Premier Alternatives

BioLoomics

Boulder, CO · Founded 2019 · Privately Held (backing)

Developer of antibody-based therapeutics designed for enhanced drug delivery in oncology. BioLoomics is based in Boulder, CO and was founded in 2019. Its last reported valuation was $22.4 million in Mar 2023. It has raised $10.4 million across 4 recorded rounds; the latest was a $450,000 seed round in Aug 2025.

Last reported valuation
$22.4M
Oct 2026
Priced at
—
Total raised
$10.4M
Last round
Seed Round
Aug 2025

BioLoomics key facts

as of Oct 2026
  • Developer of antibody-based therapeutics designed for enhanced drug delivery in oncology.
  • BioLoomics is valued at approximately $22.4M as of Oct 2026 (last reported valuation).
  • It has raised $10.4M across 4 recorded rounds; the latest was Seed Round ($450K) in Aug 2025.
  • Notable investors include Innovation Endeavors, Horizons Ventures, Hummingbird Ventures, BoxOne Ventures, Ms2 Capital — 12 tracked in total.
  • BioLoomics has filed 3 Form Ds with the SEC since 2019, most recently Mar 2023 ($9.3M sold to 23 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$22.4M

BioLoomics's last reported valuation, Mar 2023. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of BioLoomics with a free account
  • ·The complete investor list: 12 names
  • ·Watch BioLoomics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

BioLoomics funding rounds

4 rounds
Aug 2025Seed Round$450KSEC filing▮
Feb 2023Early Stage VC$9.3MSEC filing▮
May 2021Seed Round$575KSEC filing▮
May 2019Seed Round$600KSEC filing▮
Full funding history →

BioLoomics valuation

BioLoomics's last reported valuation was $22.4 million in Mar 2023. No priced round, secondary trade or fund mark has surfaced since.

How much has BioLoomics raised?

BioLoomics has raised $10.4 million across 4 recorded rounds since 2019. The largest was a $9.3 million early-stage round in Feb 2023; the most recent was a $450,000 seed round in Aug 2025.

BioLoomics has filed 3 Form Ds with the SEC since 2019, most recently in Mar 2023 ($9.3 million sold to 23 investors).

BioLoomics investors

12 investors are on record for BioLoomics, including Innovation Endeavors, Horizons Ventures, Hummingbird Ventures and BoxOne Ventures. The seed round in Aug 2025 drew 5 investors.

About BioLoomics

Developer of antibody-based therapeutics designed for enhanced drug delivery in oncology. The company's platform integrates membrane-binding peptides into antibody drug conjugates, leveraging advanced bioinformatics, AI-driven peptide design, and high-throughput screening to optimize membrane loading, internalization, and cytotoxicity, enabling pharmaceutical researchers to improve targeted drug efficacy, reduce off-target effects, and enhance therapeutic outcomes in cancer treatment

Sector
Healthcare
HQ
Boulder, CO, United States
Founded
2019
Employees
16
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.